HSP70 as a Diagnostic and Prognostic Marker in Egyptian Women With Breast Cancer |
| |
| Authors: | Hagar H. Fahim Ghada Mohamed Gehan Safwat Asmaa Abo-bakr Maher H. Ibraheem Saif Al-Mofty Mahmoud M. Kamel Ahmed S. Abdel-Moneim Abdallah M. Gameel |
| |
| Affiliation: | 1. Faculty of Biotechnology, October University for Modern Sciences and Arts, Giza, Egypt;2. Department of Surgical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt;3. Department of Pathology, Baheya Centre for Early Detection and Treatment of Breast Cancer, Giza, Egypt;4. Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt;5. Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt;6. Breast Surgery Department, Baheya Centre for Early Detection and Treatment of Breast Cancer, Giza, Egypt;7. Center of Material Science Department, Zewail City of Science and Technology, Giza, Egypt;8. Clinical Pathology Department, Baheya Centre for Early Detection and Treatment of Breast Cancer, Giza, Egypt;9. Microbiology Department, College of Medicine, Taif University, Taif, Saudi Arabia;10. Virology Department, Faculty of Veterinary Medicine, Beni-Suef University, Beni-Suef, Egypt;1. Department of Surgery, University Hospital of North Midlands, Stoke on Trent, UK;2. Department of Radiology, University Hospital of North Midlands, Stoke on Trent, UK;3. Department of Pathology, University Hospital of North Midlands, Stoke on Trent, UK;4. Department of Medicine, University of Keele, Staffordshire, UK;1. Department of Radiology, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, China;2. Deepwise AI Lab, Beijing, China;1. Department of Surgical Oncology, Breast Disease Management Group, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India;2. Breast Disease Management Group, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India;3. Department of Pathology, Breast Disease Management Group, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India;4. Department of Radiation Oncology, Breast Disease Management Group, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India;1. Postgraduate Program of Tocogynecology, Botucatu Medical School, Sao Paulo State University, UNESP, Sao Paulo, Brazil;2. Nucleous of Mastology, Barretos Cancer Hospital, Sao Paulo, Brazil;3. Postgraduate Program of Oncology, Barretos Cancer Hospital, Sao Paulo, Brazil;4. Londrina Cancer Hospital, Parana, Brazil;5. Cancer Unit, Santa Casa de Misericórdia de Itapeva, Sao Paulo, Brazil;6. Oswaldo Cruz German Hospital, Sao Paulo, Brazil;7. FACISB School of Medicine, Sao Paulo, Brazil;1. Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;2. Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, China;1. Department of Internal Medicine, Rochester General Hospital, Rochester, NY;2. Department of Hematology & Oncology, Rochester General Hospital, Rochester, NY |
| |
| Abstract: | BackgroundHeat shock protein 70 (HSP70) is a significant cellular stress response protein that has intrinsic and extrinsic pathways to protect cells against apoptosis. It is one of the most induced proteins in cancer cells. The aim of the present study is to investigate the significant role of the HSP70 expression in Egyptian patients with breast cancer (BC) and its potential to be as a diagnostic and prognostic marker.Materials and MethodsHSP70 was examined in 155 cases in this prospective study; patients were subdivided into 3 groups: 60 patients with malignant metastatic disease, 60 patients with malignant non-metastatic disease, and 35 patients with benign lesions as control. HSP70 expression was detected using enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC).ResultsMost cases of breast cancer expressed HSP70 in both serum (98.3%) and tumor tissue (90%). A strong positive correlation was found between HSP70 IHC and ELISA (r = 0.811). The mean HSP70 levels, as detected in both patients’ serum by ELISA and tumor tissue by IHC, was significantly higher in patients with BC than in benign cases (P = .001). HSP70 was significantly higher in patients with metastatic BC than in those with non-metastatic BC (P = .001). HSP70 showed positive correlation with tumor size (pT stage) and number of lymph node metastases (P ≤ .001).ConclusionHSP70 is over-expressed in patients with metastatic and non-metastatic BC than in benign cases. A high level of HSP70 either in patient’s serum or in tumor tissue correlated significantly with advanced disease in patients with BC. This present study suggests that HSP70 can serve as a BC biomarker for early screening, diagnosis, and follow-up. |
| |
| Keywords: | BC Egypt ELISA Heat shock protein 70 IHC |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
